About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Detemir Energy Expenditure Study | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 4NCT00788840

Detemir Energy Expenditure Study

This is a study designed to compare the effects of 2 long-acting insulins, detemir and insulatard, on energy expenditure,weight, fat composition, gut hormone profiles, glycaemic control and fat and mu...

Lead sponsor: University of Surrey•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of Surrey

Collaborators

Novo Nordisk A/S

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Type 2 diabetes
•2. Treated with metformin
•3. Already on treatment with a long-acting or intermediate insulin.
•4. Over 18 years of age,
•5. HbA1c \> 7.0%
•6. BMI 27-40
•7. Able and willing to perform self-blood glucose monitoring.
•8. Able and willing to maintain consistent eating habits throughout the entire trial period.
•9. Able and willing to maintain consistent physical activity level during the entire trial period

Exclusion Criteria

•1. Patients on sulphonylureas or thiazolidinediones
•2. Proliferative retinopathy that has required acute treatment within the last six months.
•3. Impaired hepatic or renal functions.
•4. Cardiac problems.
•5. Uncontrolled hypertension (treated or untreated).
•6. Mental incapacity, unwillingness or a language barrier precluding adequate understanding or co-operation.

Related studies

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more

RECRUITINGPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549 · Obesity, Overweight and/or Obesity, and more

RECRUITINGPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

RECRUITINGPhase 3

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875 · Obesity, Overweight

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 31, 2023Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE4

Enrollment30

Start dateJan 2008

Last updatedMay 31, 2023

Condition

Type 2 Diabetes Mellitus Obesity

Locations shown

Cedar Centre, Royal Surrey County Hospital

Guildford, Surrey

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 31, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions